DocMorris AG (0RRB)
London Stock Exchange · UK · prices in GBP · close of 27 Oct 2026
Key indicators
| Last close | GBP 15.10 |
|---|---|
| 52-week range | 3.92 – 16.42 |
| Return, 1 month / 3 months | +33.1% / +46.1% |
| Return, 1 year / 3 years | +180.8% / −16.0% |
| Trend | Uptrend |
| RSI (14) | 64 |
| Volatility (1 year) | 56.5% |
| Worst drawdown (1 year) | -38.8% |
| Average daily value traded | 0.74M GBP |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
DocMorris is a Swiss health-care company that runs an online pharmacy, dispensing prescription medicines and over-the-counter remedies to customers, mainly in Germany and neighbouring European markets. It also offers related health products and pharmacy services through its digital channels, connecting patients with pharmacists and medication advice. The company is based in Switzerland and serves individual consumers who order medicines and health supplies for delivery to their homes.
On this site DocMorris AG appears as a stock on the London Stock Exchange (UK), code 0RRB, with prices in pounds sterling (GBP). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
DocMorris AG (0RRB) trades on the London Stock Exchange in UK. It last closed at GBP 15.10 on 27 October 2026.
Its price-based Market X-Ray is 69 out of 100 (a fair price profile), ranking 635 of 3,788 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 180.8% and over the last three months it rose 46.1%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 93 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 81.9% | ||
| From 52-week high | -5.1% | ||
| Momentum | 97 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 46.1% | ||
| 6-month return | 115.8% | ||
| 12-month return, skipping the last month | 111.0% | ||
| Stability (higher is calmer) | 27 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 56.5% | ||
| Worst drawdown, 1 year (smaller is calmer) | -38.8% | ||
| Liquidity | 50 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.74M GBP | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | −3.2% |
|---|---|
| 1 month | +33.1% |
| 3 months | +46.1% |
| 6 months | +115.8% |
| 1 year | +180.8% |
| 3 years | −16.0% |
| 5 years | −90.0% |
Signals
| 50-day / 200-day average | 12.06 / 8.30 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.67 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.